Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment venous thromboembolic disease

Annals of Internal Medicine

Volumn 134, Issue 3, 2001, Pages

  Merli, G ^a   Spiro, T E ^a   Olsson, C G ^a   Abildgaard, U ^a   Davidson, B L ^a   Eldor, A ^a   Elias, D ^a   Grigg, A ^a   Musset, D ^a   Rodgers, G M ^a   Trowbridge, A A ^a   Yusen, R D ^a   Zawilska, K ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; AUSTRALIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; EUROPE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISRAEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNITED STATES;

EID: 0035814834     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-3-200102060-00009     Document Type: Article

References (39)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study
2. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
3. Antithrombotic therapy for venous thromboembolic disease
4. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
5. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: Second revision
6. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
7. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
8. Prevention of venous thromboembolism
9. Treatment of acute venous thromboembolism with low molecular weight hepatin (Fragmin). Results of a double-blind randomized study
10. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
11. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
12. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
13. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study
14. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
15. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)
16. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
17. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: Evaluations dans l'embolie pulmonaire
18. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
19. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
20. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis
21. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins
22. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - Dalteparin, enoxaparin and nadroparin - Administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
23. Treatment of established venous thromboembolism with enoxaparin: Preliminary report
24. An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg
25. Pharmacokinetics of enoxaparin in man given single subcutaneous doses of 1.0-1.25-1.50-2.0 mg/kg
26. Treatment of venous thromboembolism with a daily subcutaneous injection of enoxaparin: Preliminary results of a pharmacokinetic study
27. Sample size requirements for evaluating a conservative therapy
28. Design and analysis of clinical trials for anti-infective drug products
29. Points to consider: Clinical development and labeling of anti-infective drug products
30. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
31. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
32. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
33. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
34. Heparin-associated thrombocytopenia: A critical review and pooled analysis
35. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery
36. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
37. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial
38. A standard heparin nomogram for the management of heparin therapy
39. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis